Organogenesis (ORGO) Projected to Announce Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.35) per share and revenue of $54.2740 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.08). The business had revenue of $37.23 million for the quarter, compared to the consensus estimate of $43.26 million. Organogenesis had a positive return on equity of 9.63% and a negative net margin of 0.84%.

Organogenesis Stock Down 0.4%

Shares of ORGO opened at $2.52 on Thursday. The firm has a fifty day moving average price of $2.47 and a 200-day moving average price of $2.84. The company has a current ratio of 3.53, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $324.27 million, a P/E ratio of -13.26 and a beta of 1.33. Organogenesis has a 12-month low of $2.04 and a 12-month high of $7.08.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ORGO shares. BTIG Research cut shares of Organogenesis from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Weiss Ratings downgraded shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. UBS Group set a $3.00 price target on Organogenesis in a report on Thursday, May 28th. Wall Street Zen upgraded Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Finally, Truist Financial started coverage on Organogenesis in a report on Thursday, May 28th. They set a “hold” rating and a $3.00 price objective on the stock. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.75.

Institutional Trading of Organogenesis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC purchased a new position in shares of Organogenesis in the 2nd quarter valued at $24,804,000. Deutsche Bank AG boosted its position in Organogenesis by 0.4% during the fourth quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after purchasing an additional 13,301 shares in the last quarter. Geode Capital Management LLC grew its stake in Organogenesis by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock valued at $9,259,000 after purchasing an additional 62,346 shares during the last quarter. Norges Bank purchased a new position in Organogenesis in the fourth quarter valued at about $5,686,000. Finally, Bank of America Corp DE raised its holdings in Organogenesis by 27.2% in the third quarter. Bank of America Corp DE now owns 611,685 shares of the company’s stock worth $2,581,000 after purchasing an additional 130,875 shares in the last quarter. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.